These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 26456124)

  • 21. MicroRNA-126 suppresses proliferation of undifferentiated (BRAF(V600E) and BRAF(WT)) thyroid carcinoma through targeting PIK3R2 gene and repressing PI3K-AKT proliferation-survival signalling pathway.
    Rahman MA; Salajegheh A; Smith RA; Lam AK
    Exp Cell Res; 2015 Dec; 339(2):342-50. PubMed ID: 26384552
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lack of correlation between BRAF V600E mutational status and the expression profile of a distinct set of miRNAs in papillary thyroid carcinoma.
    Sheu SY; Grabellus F; Schwertheim S; Handke S; Worm K; Schmid KW
    Horm Metab Res; 2009 Jun; 41(6):482-7. PubMed ID: 19370505
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Activation of the RAS/RAF/ERK signaling pathway contributes to resistance to sunitinib in thyroid carcinoma cell lines.
    Piscazzi A; Costantino E; Maddalena F; Natalicchio MI; Gerardi AM; Antonetti R; Cignarelli M; Landriscina M
    J Clin Endocrinol Metab; 2012 Jun; 97(6):E898-906. PubMed ID: 22442268
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Integrated Analysis of Thyroid Cancer Public Datasets Reveals Role of Post-Transcriptional Regulation on Tumor Progression by Targeting of Immune System Mediators.
    Geraldo MV; Kimura ET
    PLoS One; 2015; 10(11):e0141726. PubMed ID: 26536459
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Single-cell RNA-seq analysis identifies markers of resistance to targeted BRAF inhibitors in melanoma cell populations.
    Ho YJ; Anaparthy N; Molik D; Mathew G; Aicher T; Patel A; Hicks J; Hammell MG
    Genome Res; 2018 Sep; 28(9):1353-1363. PubMed ID: 30061114
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genome-wide analysis of miRNA signature differentially expressed in doxorubicin-resistant and parental human hepatocellular carcinoma cell lines.
    Zhang J; Wang Y; Zhen P; Luo X; Zhang C; Zhou L; Lu Y; Yang Y; Zhang W; Wan J
    PLoS One; 2013; 8(1):e54111. PubMed ID: 23359607
    [TBL] [Abstract][Full Text] [Related]  

  • 27. miR-146b is highly expressed in adult papillary thyroid carcinomas with high risk features including extrathyroidal invasion and the BRAF(V600E) mutation.
    Chou CK; Chen RF; Chou FF; Chang HW; Chen YJ; Lee YF; Yang KD; Cheng JT; Huang CC; Liu RT
    Thyroid; 2010 May; 20(5):489-94. PubMed ID: 20406109
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tunicamycin induces paraptosis potentiated by inhibition of BRAFV600E in FRO anaplastic thyroid carcinoma cells.
    Kim SH; Shin HY; Kim YS; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ
    Anticancer Res; 2014 Sep; 34(9):4857-68. PubMed ID: 25202067
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A melanoma subtype with intrinsic resistance to BRAF inhibition identified by receptor tyrosine kinases gene-driven classification.
    Dugo M; Nicolini G; Tragni G; Bersani I; Tomassetti A; Colonna V; Del Vecchio M; De Braud F; Canevari S; Anichini A; Sensi M
    Oncotarget; 2015 Mar; 6(7):5118-33. PubMed ID: 25742786
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The BH3-mimetic ABT-737 sensitizes human melanoma cells to apoptosis induced by selective BRAF inhibitors but does not reverse acquired resistance.
    Wroblewski D; Mijatov B; Mohana-Kumaran N; Lai F; Gallagher SJ; Haass NK; Zhang XD; Hersey P
    Carcinogenesis; 2013 Feb; 34(2):237-47. PubMed ID: 23087082
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer.
    Vilquin P; Donini CF; Villedieu M; Grisard E; Corbo L; Bachelot T; Vendrell JA; Cohen PA
    Breast Cancer Res; 2015 Jan; 17(1):13. PubMed ID: 25633049
    [TBL] [Abstract][Full Text] [Related]  

  • 32. miR-514a regulates the tumour suppressor NF1 and modulates BRAFi sensitivity in melanoma.
    Stark MS; Bonazzi VF; Boyle GM; Palmer JM; Symmons J; Lanagan CM; Schmidt CW; Herington AC; Ballotti R; Pollock PM; Hayward NK
    Oncotarget; 2015 Jul; 6(19):17753-63. PubMed ID: 25980496
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The c-Jun/RHOB/AKT pathway confers resistance of BRAF-mutant melanoma cells to MAPK inhibitors.
    Delmas A; Cherier J; Pohorecka M; Medale-Giamarchi C; Meyer N; Casanova A; Sordet O; Lamant L; Savina A; Pradines A; Favre G
    Oncotarget; 2015 Jun; 6(17):15250-64. PubMed ID: 26098773
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.
    Yang H; Higgins B; Kolinsky K; Packman K; Bradley WD; Lee RJ; Schostack K; Simcox ME; Kopetz S; Heimbrook D; Lestini B; Bollag G; Su F
    Cancer Res; 2012 Feb; 72(3):779-89. PubMed ID: 22180495
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nuclear factor-{kappa}B contributes to anaplastic thyroid carcinomas through up-regulation of miR-146a.
    Pacifico F; Crescenzi E; Mellone S; Iannetti A; Porrino N; Liguoro D; Moscato F; Grieco M; Formisano S; Leonardi A
    J Clin Endocrinol Metab; 2010 Mar; 95(3):1421-30. PubMed ID: 20061417
    [TBL] [Abstract][Full Text] [Related]  

  • 36. BRAF associated autophagy exploitation: BRAF and autophagy inhibitors synergise to efficiently overcome resistance of BRAF mutant colorectal cancer cells.
    Goulielmaki M; Koustas E; Moysidou E; Vlassi M; Sasazuki T; Shirasawa S; Zografos G; Oikonomou E; Pintzas A
    Oncotarget; 2016 Feb; 7(8):9188-221. PubMed ID: 26802026
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hyalinizing trabecular tumour of the thyroid-differential expression of distinct miRNAs compared with papillary thyroid carcinoma.
    Sheu SY; Vogel E; Worm K; Grabellus F; Schwertheim S; Schmid KW
    Histopathology; 2010 Apr; 56(5):632-40. PubMed ID: 20459574
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Altered expression of mir-222 and mir-25 influences diverse gene expression changes in transformed normal and anaplastic thyroid cells, and impacts on MEK and TRAIL protein expression.
    Aherne ST; Smyth P; Freeley M; Smith L; Spillane C; O'Leary J; Sheils O
    Int J Mol Med; 2016 Aug; 38(2):433-45. PubMed ID: 27353001
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Propranolol sensitizes thyroid cancer cells to cytotoxic effect of vemurafenib.
    Wei WJ; Shen CT; Song HJ; Qiu ZL; Luo QY
    Oncol Rep; 2016 Sep; 36(3):1576-84. PubMed ID: 27432558
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Prostate Cancer Cells Resistant to Docetaxel as in vitro Model for Discovering MicroRNAs Predictive of the Onset of Docetaxel Resistance.
    Bascetta L; Oliviero A; D'Aurizio R; Evangelista M; Mercatanti A; Pellegrini M; Marrocolo F; Bracarda S; Rizzo M
    Int J Mol Sci; 2017 Jul; 18(7):. PubMed ID: 28703747
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.